MX393605B - Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo - Google Patents
Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismoInfo
- Publication number
- MX393605B MX393605B MX2017016329A MX2017016329A MX393605B MX 393605 B MX393605 B MX 393605B MX 2017016329 A MX2017016329 A MX 2017016329A MX 2017016329 A MX2017016329 A MX 2017016329A MX 393605 B MX393605 B MX 393605B
- Authority
- MX
- Mexico
- Prior art keywords
- mother
- peptides
- maternal autoantibodies
- potential
- ldh
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 206010003805 Autism Diseases 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 230000008774 maternal effect Effects 0.000 abstract 4
- 102100022188 Dihydropyrimidinase-related protein 1 Human genes 0.000 abstract 2
- 102100024426 Dihydropyrimidinase-related protein 2 Human genes 0.000 abstract 2
- 108010012029 Guanine Deaminase Proteins 0.000 abstract 2
- 102000013587 Guanine deaminase Human genes 0.000 abstract 2
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 abstract 2
- 101710140918 Stress-induced-phosphoprotein 1 Proteins 0.000 abstract 2
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 abstract 2
- 102000009266 Y-Box-Binding Protein 1 Human genes 0.000 abstract 2
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- 108010022820 collapsin response mediator protein-1 Proteins 0.000 abstract 2
- 108010022822 collapsin response mediator protein-2 Proteins 0.000 abstract 2
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 abstract 1
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a péptidos que se unen específicamente a anticuerpos maternos que son generados en la madre o madre potencial contra uno o más antígenos polipeptídicos endógenos seleccionados de lactato deshidrogenasa A (LDH A), lactato deshidrogenasa B (LDH B), fosfoproteína producida por tensión 1 (STPIP1), guanina desaminasa (GDA), proteína de unión de la casilla Y 1(YB X1), proteína mediadora de la respuesta a la colapsina 1 (CRMP1) y proteína mediadora de la respuesta a la colapsina 2 (CRMP2). Los polipéptidos descritos en la presente son útiles para determinar un riesgo de que un descendiente desarrolle un trastorno del espectro de autista (ASD) detectando la presencia de anticuerpos maternos en una muestra biológica de la madre o madre potencial. Los péptidos o mimotopos de los mismos pueden ser administrados también a la madre o madre potencial para bloquear la unión entre los anticuerpos maternos y sus antígenos, neutralizando por los tanto los anticuerpos maternos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185186P | 2015-06-26 | 2015-06-26 | |
| PCT/US2016/039029 WO2016210137A1 (en) | 2015-06-26 | 2016-06-23 | Antigenic peptides and uses thereof for diagnosing and treating autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016329A MX2017016329A (es) | 2018-08-15 |
| MX393605B true MX393605B (es) | 2025-03-24 |
Family
ID=57585879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016329A MX393605B (es) | 2015-06-26 | 2016-06-23 | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo |
| MX2022008215A MX2022008215A (es) | 2015-06-26 | 2017-12-14 | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008215A MX2022008215A (es) | 2015-06-26 | 2017-12-14 | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11098082B2 (es) |
| EP (2) | EP3314258B1 (es) |
| JP (1) | JP6873060B2 (es) |
| CN (1) | CN108184330B (es) |
| AU (1) | AU2016281649B2 (es) |
| CA (1) | CA2989882A1 (es) |
| ES (1) | ES2964981T3 (es) |
| HK (1) | HK1254818A1 (es) |
| MX (2) | MX393605B (es) |
| WO (1) | WO2016210137A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011019929A1 (en) | 2009-08-14 | 2011-02-17 | The Regents Of The University Of California | Methods of diagnosing and treating autism |
| EP3314258B1 (en) | 2015-06-26 | 2023-11-15 | The Regents of the University of California | Antigenic peptides and uses thereof for diagnosing and treating autism |
| CN114450399A (zh) * | 2019-05-02 | 2022-05-06 | 卢万天主教大学 | 用于治疗癌症的乳酸脱氢酶抑制剂多肽 |
| EP4065977A4 (en) * | 2019-11-25 | 2023-12-27 | The Regents of the University of California | ANTIGEN NEURON-SPECIFIC ENOLASE PEPTIDES FOR THE DIAGNOSIS AND TREATMENT OF AUTISM |
| CN113238045B (zh) * | 2021-04-27 | 2021-12-28 | 南方医科大学南方医院 | Crmp2及抗crmp2抗体的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| US20030064411A1 (en) * | 2000-12-08 | 2003-04-03 | Herath Herath Mudiyanselage Athula Chandrasiri | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease |
| EP1379879A2 (en) * | 2000-12-08 | 2004-01-14 | Oxford GlycoSciences (UK) Limited | Diagnosis and treatment of alzheimer's disease |
| JP2005507242A (ja) | 2001-06-08 | 2005-03-17 | インサイト・ゲノミックス・インコーポレイテッド | 細胞内シグナル伝達分子 |
| WO2003022298A2 (fr) * | 2001-09-07 | 2003-03-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CA2511816A1 (en) * | 2002-12-26 | 2004-07-22 | Cemines, Inc. | Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| US7452678B2 (en) | 2003-06-24 | 2008-11-18 | Bristol-Myers Squibb Company | Identification of biomarkers for liver toxicity |
| WO2005007090A2 (en) | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| CN103397019A (zh) | 2003-11-21 | 2013-11-20 | 雷维维科公司 | 干扰rna在生产转基因动物中的用途 |
| EP1859266A4 (en) * | 2005-02-24 | 2010-07-28 | Cemines Inc | COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES |
| US7604948B2 (en) | 2005-05-05 | 2009-10-20 | The Regents Of The University Of California | Biomarkers for diagnosing an autism spectrum disorder |
| US7452681B2 (en) | 2005-05-05 | 2008-11-18 | The Regents Of The University Of California | Diagnostic methods for the detection of autism spectrum disorder |
| GB0524609D0 (en) | 2005-12-02 | 2006-01-11 | Univ Cambridge Tech | Methods of monitoring and diagnosing psychotic disorders and of identifying biomarkers for psychotic disorders |
| GB0602992D0 (en) | 2006-02-15 | 2006-03-29 | Morvus Technology Ltd | Methods, genes and proteins |
| CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US8257929B2 (en) | 2006-10-20 | 2012-09-04 | University Of Miami | Gene expression profiling of Parkinson's Disease |
| JP5298858B2 (ja) | 2007-02-16 | 2013-09-25 | 株式会社島津製作所 | 上皮性卵巣癌の組織型識別マーカー、及びそれを用いた組織型に基づく上皮性卵巣癌の罹患の識別法 |
| WO2008118350A1 (en) * | 2007-03-23 | 2008-10-02 | Advpharma, Inc. | Compositions and methods of using crmp-1 and its fragments for treating cancer |
| EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| WO2009075883A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
| WO2011019929A1 (en) * | 2009-08-14 | 2011-02-17 | The Regents Of The University Of California | Methods of diagnosing and treating autism |
| US20140134187A1 (en) * | 2012-06-25 | 2014-05-15 | The Johns Hopkins University | Therapeutic and diagnostic methods for autism spectrum disorders and other conditions |
| EP3314258B1 (en) | 2015-06-26 | 2023-11-15 | The Regents of the University of California | Antigenic peptides and uses thereof for diagnosing and treating autism |
-
2016
- 2016-06-23 EP EP16815305.4A patent/EP3314258B1/en active Active
- 2016-06-23 MX MX2017016329A patent/MX393605B/es unknown
- 2016-06-23 EP EP23204324.0A patent/EP4300101A3/en active Pending
- 2016-06-23 CA CA2989882A patent/CA2989882A1/en active Pending
- 2016-06-23 AU AU2016281649A patent/AU2016281649B2/en active Active
- 2016-06-23 CN CN201680037784.2A patent/CN108184330B/zh active Active
- 2016-06-23 HK HK18113905.7A patent/HK1254818A1/zh unknown
- 2016-06-23 JP JP2017567250A patent/JP6873060B2/ja active Active
- 2016-06-23 WO PCT/US2016/039029 patent/WO2016210137A1/en not_active Ceased
- 2016-06-23 ES ES16815305T patent/ES2964981T3/es active Active
-
2017
- 2017-12-14 MX MX2022008215A patent/MX2022008215A/es unknown
- 2017-12-19 US US15/847,477 patent/US11098082B2/en active Active
-
2021
- 2021-07-16 US US17/378,401 patent/US20210347824A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016281649A1 (en) | 2018-01-18 |
| CN108184330A (zh) | 2018-06-19 |
| WO2016210137A1 (en) | 2016-12-29 |
| HK1254818A1 (zh) | 2019-07-26 |
| ES2964981T3 (es) | 2024-04-10 |
| EP3314258A4 (en) | 2019-04-10 |
| JP6873060B2 (ja) | 2021-05-19 |
| US20210347824A1 (en) | 2021-11-11 |
| AU2016281649B2 (en) | 2022-08-04 |
| MX2017016329A (es) | 2018-08-15 |
| EP4300101A3 (en) | 2024-03-20 |
| EP4300101A2 (en) | 2024-01-03 |
| MX2022008215A (es) | 2022-08-04 |
| JP2018529630A (ja) | 2018-10-11 |
| EP3314258B1 (en) | 2023-11-15 |
| CN108184330B (zh) | 2021-08-06 |
| US11098082B2 (en) | 2021-08-24 |
| CA2989882A1 (en) | 2016-12-29 |
| EP3314258A1 (en) | 2018-05-02 |
| US20180194807A1 (en) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008215A (es) | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. | |
| Becker et al. | Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| MX2021013681A (es) | Moleculas de union a lag-3 y metodos de uso de las mismas. | |
| MX389083B (es) | Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet. | |
| JO3812B1 (ar) | أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1) | |
| TW201613637A (en) | Methods of treating Alzheimer's Disease | |
| EA201891294A1 (ru) | Способ, в котором используется биспецифический белковый комплекс | |
| MX2021006791A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
| MX2014004794A (es) | Seleccion de protocolo preferido de manejo y procesamiento de muestras para identificacion de biomarcadores de enfermedad y valoracion de calidad de muestra. | |
| RU2015120601A (ru) | Эритроферрон и erfe-полипептиды и способы регуляции метаболизма железа | |
| CY1121169T1 (el) | Αντισωμα που δεσμευει ενα γραμμικο επιτοπο ανθρωπινου ρ53 και διαγνωστικες εφαρμογες αυτου | |
| WO2016198833A3 (en) | Methods for analysing a urine sample | |
| BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| WO2015166353A3 (en) | Early detection of preeclampsia | |
| EP2913675A3 (en) | GP2 isoforms and their use in autoantibody capture | |
| BR112017002575A2 (pt) | método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo | |
| EA202190671A1 (ru) | Иммуногенетическая скрининговая проба на рак | |
| EP3448881A4 (en) | TREATMENT OF MUTANT TUMORS OF THE HIPPO PATHWAY AND METHODS OF IDENTIFYING SUBJECTS AS CANDIDATES FOR TREATMENT | |
| BR112017011724A2 (pt) | ensaio para detectar dpp-4 humana | |
| PL409521A1 (pl) | Wykorzystanie panelu 94 autoprzeciwciał jako klasyfikatora w nieinwazyjnej diagnostyce prenatalnej aberracji chromosomowej Zespołu Downa oparte o analizę we krwi | |
| PL409522A1 (pl) | Wykorzystanie panelu 14 autoprzeciwciał jako klasyfikatora w nieinwazyjnej diagnostyce prenatalnej aberracji chromosomowej Zespołu Downa oparte o analizę we krwi | |
| Shang et al. | Evaluation of Diagnostic Value of Antibody Against Aspergillus Fumigatus Pectate Lyase A for Invasive Aspergillosis |